TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31220942

Group type: EXPERIMENTAL
Intervention: S100a9 neutralizing antibody administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockout of S100a9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hematopoietic overexpression of S100a9
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic serum S100a8/a9 levels measurement
Number of subjects: 0
Study: 31221129

Group type: EXPERIMENTAL
Intervention: MIND questionnaire
Number of subjects: 128
Study: 31221215

Group type: EXPERIMENTAL
Intervention: Virtual community of practice (vCoP) for primary care professionals
Number of subjects: 12
Study: 31221542

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 779
Study: 31221711

Group type: EXPERIMENTAL
Intervention: Smartphone-Based, Patient-Centered Diabetes Care System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 31221778

Group type: EXPERIMENTAL
Intervention: New drugs
Number of subjects: 2332

Group type: EXPERIMENTAL
Intervention: Presence of extramedullary disease
Number of subjects: 2332
Study: 31221874

Group type: EXPERIMENTAL
Intervention: Multicentric longitudinal observational study of children with ASD
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Clinical examination and battery of clinical tools (Autism Diagnostic Observation Schedule, revised Autism Diagnostic Interview, measures of intellectual functioning, behavioral and developmental measurements)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Follow-up assessments at 18 months, 3 years, 4.5 years, and 6 years after baseline examination
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires completed by parents
Number of subjects: 1000
Study: 31221878

Group type: EXPERIMENTAL
Intervention: Healthcare-associated or nosocomial infection (HAI) cases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-HAI cases (control group)
Number of subjects: 0
Study: 31222633

Group type: EXPERIMENTAL
Intervention: Rockall scores ≥6 group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Rockall scores <6 group
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Rockall scores ≥6 group (per-protocol analysis)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Rockall scores <6 group (per-protocol analysis)
Number of subjects: 140
Study: 31222663

Group type: EXPERIMENTAL
Intervention: Clinical group (CKD patients with psychosocial adjustment or mental health problems)
Number of subjects: 166
Study: 31222714

Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 1514

Group type: COMPARATOR
Intervention: Antimuscarinics
Number of subjects: 1514
Study: 31222720

Group type: EXPERIMENTAL
Intervention: G-estimation using a quadratic approximation approach inspired by iteratively reweighted least squares.
Number of subjects: 0
Study: 31222722

Group type: EXPERIMENTAL
Intervention: CUSP9-LD (low-dose CUSP9) combined with Bcl-2/Bcl-xL inhibitor ABT263
Number of subjects: 0

Group type: COMPARATOR
Intervention: CUSP9-LD
Number of subjects: 0
Study: 31222783

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin for 12 weeks (genotype 2) or 24 weeks (genotype 3); Sofosbuvir dosage: 150 mg for patients aged 3 to <6 years weighing <17 kg, 200 mg for patients aged 3 to <6 years weighing ≥17 kg and all patients aged 6 to <12 years; Ribavirin dosing based on weight (up to 1,400 mg/day, two divided doses).
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin
Number of subjects: 54
Study: 31223191

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AER)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (ECC)
Number of subjects: 16
Study: 31225429

Group type: EXPERIMENTAL
Intervention: DMARD withdrawal
Number of subjects: 13
Study: 31225583

Group type: EXPERIMENTAL
Intervention: Measured Total Energy Expenditure (TEE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Energy recommendation of 25 kcal/kg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Dietary Reference Intakes (DRIs)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Physical Activity Level (PAL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hypermetabolism defined as REE > 110% of predicted
Number of subjects: 21
Study: 31225610

Group type: EXPERIMENTAL
Intervention: Analytical treatment interruption (ATI)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Resumption of ART after confirmed viral rebound
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Baseline factors
Number of subjects: 9
Study: 31225870

Group type: EXPERIMENTAL
Intervention: Atg7 knockdown in 3T3-L1 adipocytes
Number of subjects: 183

Group type: COMPARATOR
Intervention: High-calorie diet in mice
Number of subjects: 183

Group type: COMPARATOR
Intervention: Human subcutaneous adipose tissue ATG7 mRNA expression
Number of subjects: 183

Group type: COMPARATOR
Intervention: Single nucleotide polymorphism Rs2606729 in ATG7
Number of subjects: 183
Study: 31225872

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) treatment of MCF7 cells
Number of subjects: 6

Group type: COMPARATOR
Intervention: GR antagonist RU486
Number of subjects: 6

Group type: COMPARATOR
Intervention: Actinomycin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Defective 501H GR mutant
Number of subjects: 6
Study: 31226260

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-ADHD
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ADHD participants
Number of subjects: 46
Study: 31226985

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Other approved therapies
Number of subjects: 2500
Study: 31227534

Group type: EXPERIMENTAL
Intervention: Highly-interventional spasticity management (including SDR, ITB, anti-spasticity injections and medications)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimally-interventional spasticity management (no SDR)
Number of subjects: 0
Study: 31227585

Group type: COMPARATOR
Intervention: Family-based lifestyle and psycho-educational intervention program (control intervention)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Supervised exercise in addition to the family-based lifestyle and psycho-educational intervention program
Number of subjects: 116
Study: 31228053

Group type: EXPERIMENTAL
Intervention: No-cost diagnostic colonoscopy arranged through telephonic navigation after abnormal FIT results.
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Reasons for not completing follow-up colonoscopy among non-completers.
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Previous colonoscopy completion status among non-completers.
Number of subjects: 689

Group type: EXPERIMENTAL
Intervention: Reasons for non-completion without reported barriers.
Number of subjects: 689
Study: 31228090

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 607

Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Dulaglutide (both doses)
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 607
Study: 31228100

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Adalimumab 40 mg biweekly
Number of subjects: 1305
Study: 31228101

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg no-load
Number of subjects: 341

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg or 150 mg no-load
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg (after dose escalation)
Number of subjects: 341
Study: 31228176

Group type: EXPERIMENTAL
Intervention: Digital physiotherapy (PT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 66
Study: 31228177

Group type: EXPERIMENTAL
Intervention: SMART4MD app on a data-enabled computer tablet, used daily at home.
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 1200
Study: 31228214

Group type: EXPERIMENTAL
Intervention: Alcoholic hepatitis patients with ASCA levels ≥34 IU/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcoholic hepatitis patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol use disorder patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonalcoholic controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcoholic hepatitis and alcohol use disorder groups
Number of subjects: 0
Study: 31228626

Group type: EXPERIMENTAL
Intervention: Durvalumab 10 mg/kg every 2 weeks for 12 months
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 304
Study: 31228628

Group type: EXPERIMENTAL
Intervention: Ig20Gly infusion at rates of ≥60 mL/h/site
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ig20Gly infusion
Number of subjects: 0
Study: 31228640

Group type: EXPERIMENTAL
Intervention: Cannabis users
Number of subjects: 390

Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 390
Study: 31228943

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation with 250 ml albumin 5% boluses repeated as required to restore PPV to < 15% (Fluid non-Responding Status - FnRS)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Pulse pressure variations (PPV) of ≥15% indicating fluid resuscitation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Simultaneous blood samples from central venous and pulmonary artery catheters (PAC)
Number of subjects: 67
Study: 31228957

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD) for 1 month
Number of subjects: 18
Study: 31229394

Group type: EXPERIMENTAL
Intervention: pARC
Number of subjects: 2089

Group type: COMPARATOR
Intervention: PAS
Number of subjects: 2089
Study: 31229429

Group type: EXPERIMENTAL
Intervention: Triton system (Gauss Surgical, Inc)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Subjective estimated blood loss
Number of subjects: 242
Study: 31230508

Group type: EXPERIMENTAL
Intervention: Women with heart failure with preserved ejection fraction
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Pulse pressure in women
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Men with heart failure with preserved ejection fraction
Number of subjects: 654
Study: 31230614

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Isosulfane blue (ISB)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard sectioning
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Ultrastaging
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Overall SLN identification
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Bilateral mapping
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Negative predictive value (NPV)
Number of subjects: 204
Study: 31230767

Group type: EXPERIMENTAL
Intervention: Surgeon-dominated approach to design of 3D-printed patient-specific surgical plates
Number of subjects: 16
Study: 31231065

Group type: EXPERIMENTAL
Intervention: Segesterone acetate and ethinylestradiol contraceptive vaginal system (0.15 mg segesterone acetate and 0.013 mg ethinylestradiol per day) used for 13 cycles (1 year)
Number of subjects: 2278
Study: 31231122

Group type: EXPERIMENTAL
Intervention: RRx-001 4 mg IV on day 1 of each week of a 21-day cycle followed by platinum plus etoposide (80-100 mg IV) at progression
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 26
Study: 31231276

Group type: EXPERIMENTAL
Intervention: Ayahuasca
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31231311

Group type: EXPERIMENTAL
Intervention: Novel Continuous Remote Care Intervention Including Nutritional Ketosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31231443

Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy (PRRT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2
Study: 31231656

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 31231785

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg daily for 12 weeks
Number of subjects: 19
Study: 31231944

Group type: EXPERIMENTAL
Intervention: Heartech® left ventricular partitioning device (LVPD)
Number of subjects: 16
Study: 31233323

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) intervention, details on dosage and duration not available.
Number of subjects: 0
Study: 31233347

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study: 31233392

Group type: EXPERIMENTAL
Intervention: Chronic hypertension
Number of subjects: 100

Group type: COMPARATOR
Intervention: No chronic hypertension
Number of subjects: 100
Study: 31233744

Group type: EXPERIMENTAL
Intervention: New objective CT analysis tool combining densitometry with machine learning
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: New objective CT analysis tool
Number of subjects: 297
Study: 31234786

Group type: EXPERIMENTAL
Intervention: Severity of Dependence Scale (SDS)
Number of subjects: 246
Study: 31234866

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) assessed by ActiGraph GT3X+ accelerometer over 7 days, average time of MVPA was 34.88 min/day.
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) in Costa Rica and Peru.
Number of subjects: 2370
Study: 31235325

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 104
Study: 31235405

Group type: EXPERIMENTAL
Intervention: Cal09 LAIV
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: NY15 LAIV
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: NY15 LAIV (seronegative children)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Persistent shedding to day 7
Number of subjects: 253
Study: 31235441

Group type: EXPERIMENTAL
Intervention: Ribociclib (400 mg per day continuously) plus trastuzumab (6 mg/kg every 3 weeks)
Number of subjects: 13
Study: 31235483

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy plus biweekly cetuximab as first-line therapy
Number of subjects: 181

Group type: COMPARATOR
Intervention: Clinical score with clinical variables only
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Clinical score with clinical variables and BRAF mutational status
Number of subjects: 181
Study: 31235630

Group type: EXPERIMENTAL
Intervention: High-dose ceftriaxone (75 to 100 mg/kg of body weight/day)
Number of subjects: 153
Study: 31235775

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BVZ) added to chemotherapy plus trastuzumab (Trast)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy plus trastuzumab (Trast)
Number of subjects: 0
Study: 31235963

Group type: EXPERIMENTAL
Intervention: T cell receptor gene therapy targeting WT1
Number of subjects: 0
Study: 31236272

Group type: EXPERIMENTAL
Intervention: HPV vaccinated group
Number of subjects: 409

Group type: COMPARATOR
Intervention: HPV unvaccinated group
Number of subjects: 409

Group type: COMPARATOR
Intervention: Unvaccinated women
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 409
Study: 31236579

Group type: EXPERIMENTAL
Intervention: Toripalimab (3 mg/kg d1, Q2W) as monotherapy in cohort 1
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Toripalimab (360 mg d1, Q3W) with oxaliplatin (130 mg/m2 qd, d1) and capecitabine (1000 mg/m2 b.i.d., d1-d14, Q3W) in cohort 2
Number of subjects: 76
Study: 31236601

Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat-based regimen
Number of subjects: 761
Study: 31236809

Group type: EXPERIMENTAL
Intervention: Breast compression
Number of subjects: 31
Study: 31236847

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab therapy
Number of subjects: 12
Study: 31236954

Group type: EXPERIMENTAL
Intervention: 15-min massage protocol applied by parents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual medical and nursing care given by neonatal units
Number of subjects: 0
Study: 31237173

Group type: EXPERIMENTAL
Intervention: Defect-free care (implementation of all 8 AIS processes of care)
Number of subjects: 9485
Study: 31237206

Group type: EXPERIMENTAL
Intervention: Gene therapy for Leber's hereditary optic neuropathy
Number of subjects: 3
Study: 31237839

Group type: EXPERIMENTAL
Intervention: Tailored Motivational Interviewing (TMI) implementation intervention (workshop and trigger-based coaching)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of internal facilitator coaching with encouragement of communities of practice (CoPs)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Communities of practice (CoPs) alone
Number of subjects: 150
Study: 31237841

Group type: EXPERIMENTAL
Intervention: Seva (mHealth intervention)
Number of subjects: 268
Study: 31238830

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) with or without intravenous tPA (IVT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous tPA (IVT) only
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Revascularization patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-revascularization patients
Number of subjects: 50
Study: 31238832

Group type: EXPERIMENTAL
Intervention: Multiple thrombectomy passes
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single thrombectomy pass
Number of subjects: 80
Study: 31238992

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 24
Study: 31239281

Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 24131

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 24131
Study: 31239311

Group type: EXPERIMENTAL
Intervention: Oxaliplatin and capecitabine (XELOX) plus D2 gastrectomy
Number of subjects: 54
Study: 31239315

Group type: EXPERIMENTAL
Intervention: Less-experienced emergency physicians (≤10 years)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Experienced emergency physicians (>10 years)
Number of subjects: 319
Study: 31239326

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Higher baseline Alberta Stroke Program Early CT score (ASPECTS)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: IV-tPA
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Prolonged time to treatment
Number of subjects: 389
Study: 31239657

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31239736

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 31239857

Group type: EXPERIMENTAL
Intervention: Laser Auriculotherapy (LAT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Magneto-Auriculotherapy (MAT)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Combination of LAT and MAT
Number of subjects: 145
Study: 31240302

Group type: EXPERIMENTAL
Intervention: Zolbetuximab (monoclonal antibody) administered intravenously every 2 weeks for five planned infusions; cohorts received doses of 1300 mg/m2, 2600 mg/m2, and 3600 mg/m2.
Number of subjects: 54
Study: 31240499

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) monotherapy or combination therapy
Number of subjects: 0
Study: 31240688

Group type: EXPERIMENTAL
Intervention: Vancomycin plus piperacillin-tazobactam
Number of subjects: 723

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam alone
Number of subjects: 723

Group type: COMPARATOR
Intervention: Vancomycin alone
Number of subjects: 723
Study: 31241031

Group type: EXPERIMENTAL
Intervention: Environmental stimulation (specifically stimulation specificity)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Environmental feedback
Number of subjects: 104
Study: 31241490

Group type: EXPERIMENTAL
Intervention: Enzyme immunoassay (EIA) and chemiluminescence assay (CLIA) for IgM and IgG against B. burgdorferi
Number of subjects: 535
Study: 31241558

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31241745

Group type: EXPERIMENTAL
Intervention: Uterus donation for transplantation
Number of subjects: 9
Study: 31242023

Group type: EXPERIMENTAL
Intervention: Isoproterenol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study: 31242362

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I concentrations of less than 6 ng per liter and an absolute change of less than 4 ng per liter after 45 to 120 minutes (early serial sampling)
Number of subjects: 22651

Group type: EXPERIMENTAL
Intervention: Risk-assessment tool based on high-sensitivity troponin I or T concentration at presentation and dynamic change during serial sampling
Number of subjects: 22651
Study: 31242746

Group type: EXPERIMENTAL
Intervention: Novel ultrasound imaging and charge density mapping system for ablation of nonpulmonary vein targets
Number of subjects: 127
Study: 31242863

Group type: EXPERIMENTAL
Intervention: Capillary blood smears
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Venous blood smears
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Multiple polymorphic markers
Number of subjects: 223
Study: 31242873

Group type: EXPERIMENTAL
Intervention: STARPAC design
Number of subjects: 0

Group type: COMPARATOR
Intervention: TITE-CRM
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3+3 design
Number of subjects: 0
Study: 31242877

Group type: EXPERIMENTAL
Intervention: Integration of depression management into routine HIV care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard HIV care without integrated depression management
Number of subjects: 0
Study: 31243036

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy-derived regional cerebral oxygenation (rSO2) measurement for 72 hours
Number of subjects: 0
Study: 31243801

Group type: EXPERIMENTAL
Intervention: In-home respite care program
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard dementia care
Number of subjects: 99
Study: 31244718

Group type: EXPERIMENTAL
Intervention: Natural menstrual cycle
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fertility treatment (supraphysiological estradiol levels)
Number of subjects: 44
Study: 31244760

Group type: EXPERIMENTAL
Intervention: CX-8998, a selective modulator of the T-Type calcium channel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0